Compounds > pyrazines
Page last updated: 2024-08-21

pyrazines and Leukemia, Pre-B-Cell

pyrazines has been researched along with Leukemia, Pre-B-Cell in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (87.50)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Accordi, B; Basso, G; Bresolin, S; Cortese, G; Mariotto, E; Porcù, E; Serafin, V; Veltri, G1
Becker, A; Chabanovska, O; Junghanss, C; Murua Escobar, H; Ngezahayo, A; Sekora, A; Sender, S; Villa Perez, S1
Levy, Y; Maisel, C; Robinson, S; Tong, AW1
Abbenante, MC; Derenzini, E; Ferrari, A; Ghelli Luserna Di Rorà, A; Guadagnuolo, V; Iacobucci, I; Imbrogno, E; Martinelli, G; Paolini, S; Papayannidis, C; Parisi, S; Robustelli, V; Sartor, C1
Badowska, W; Czyzewski, K; Juraszewska, E; Konatkowska, B; Kuzmicz, M; Malinowska, I; Olejnik, I; Pogorzala, M; Sobol, G; Stanczak, E; Stefaniak, J; Styczynski, J; Szczepanek, J; Szczepanski, T; Wysocki, M1
Bendall, LJ; Bradstock, KF; Cisterne, A; Saunders, P; Weiss, J1
Chen, ST; Dewar, R; Khosravi-Far, R; Miller, K; Yeckes-Rodin, H1
Bostrom, BC; Eckroth, E; Gaynon, PS; Malvar, J; Messinger, YH; Sposto, R; van der Giessen, J1

Trials

1 trial(s) available for pyrazines and Leukemia, Pre-B-Cell

ArticleYear
Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
    Blood, 2012, Jul-12, Volume: 120, Issue:2

    Topics: Adolescent; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Boronic Acids; Bortezomib; Child; Child, Preschool; Dexamethasone; Doxorubicin; Female; Humans; Infant; Kaplan-Meier Estimate; Male; Opportunistic Infections; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Recurrence; Remission Induction; Treatment Outcome; Vincristine; Young Adult

2012

Other Studies

7 other study(ies) available for pyrazines and Leukemia, Pre-B-Cell

ArticleYear
SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric
    International journal of molecular sciences, 2019, Dec-07, Volume: 20, Issue:24

    Topics: Aminopyridines; Cell Proliferation; Child; Core Binding Factor Alpha 2 Subunit; Cyclohexylamines; Drug Resistance, Neoplasm; Humans; Indazoles; Morpholines; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Oxazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrimidines; Syk Kinase; Tumor Cells, Cultured

2019
Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib.
    International journal of molecular sciences, 2021, Jan-08, Volume: 22, Issue:2

    Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Gene Expression Regulation, Leukemic; Humans; Indazoles; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cells, B-Lymphoid; Pyrazines; Sequence Analysis, RNA; Syk Kinase

2021
Haematological complete remission by ponatinib and bortezomib in a patient with relapsed, Ph⁺ pre-B acute lymphoblastic leukaemia.
    BMJ case reports, 2014, Apr-12, Volume: 2014

    Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Imidazoles; Male; Philadelphia Chromosome; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Pyridazines; Recurrence; Remission Induction

2014
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.
    Oncotarget, 2016, Aug-16, Volume: 7, Issue:33

    Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Checkpoint Kinase 2; Clofarabine; Dasatinib; Drug Synergism; Humans; Imatinib Mesylate; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrazines; Pyrazoles

2016
Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia.
    Anticancer research, 2010, Volume: 30, Issue:6

    Topics: Adolescent; Antineoplastic Agents; Boronic Acids; Bortezomib; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines

2010
The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.
    Haematologica, 2011, Volume: 96, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Everolimus; Humans; Immunosuppressive Agents; Leupeptins; Mice; Mice, Inbred NOD; Mice, SCID; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protease Inhibitors; Pyrazines; Radiation, Ionizing; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases; Whole-Body Irradiation

2011
Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker.
    Cancer biology & therapy, 2011, Mar-15, Volume: 11, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Fusion Proteins, bcr-abl; Humans; Male; Middle Aged; Philadelphia Chromosome; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Remission Induction; Young Adult

2011